Publication Details
Publication: Health Life Business (ヘルスライフビジネス), No. 846
Publication Date: March 1, 2025
Original Language: Japanese
English Translation of the Published Article
Note: The following English text is a faithful rendering of the information presented in the original Japanese media article. The content reflects the original media coverage.
Health Life Business featured Toei Shinyaku’s Agaricus KA21 research in an article describing the ingredient’s expansion into femtech and men’s health. The article introduces the company’s long-term research program and the accumulation of international scientific publications on KA21.
It describes a study involving 24 men aged 50–69 years who consumed 900 mg of Agaricus KA21 per day for two months. The article reports evaluations related to aging symptoms, male sexual function and hair-related concerns.
The article also introduces research on ovarian function using a Drosophila model conducted with academic collaborators. Toei Shinyaku filed a Japanese patent application related to suppression of age-associated decline in ovarian function based on this research.
By presenting research in both men’s and women’s health, the article characterizes KA21 as an ingredient whose research applications are expanding beyond its traditional positioning.
日本語記事概要 / Japanese Summary
『ヘルスライフビジネス』2025年3月1日号で、露地栽培アガリクスKA21の研究がメンズヘルス、フェムテック領域へ広がっていることが紹介されました。50～69歳男性24名を対象とした900mg/日・2か月の研究や、男性のQOLに関連する評価、大学との共同による卵巣機能研究、関連する特許出願などが取り上げられています。